The System reduces the time for UTI diagnosis to just 15 minutes and determines optimal antibiotics within 30 minutes. A recently published analysis suggests potential healthcare savings based on modelled projections in Spain. Recognised with the £8 million Longitude Prize, this innovative tool is reshaping approaches to AMR globally.
Sysmex is leading the way in medical diagnostics with the PA-100 AST System, a rapid solution for detecting and treating uncomplicated urinary tract infections. Through cutting-edge nanofluidic technology and rapid antimicrobial susceptibility testing (AST), the device produces actionable results in just 45 minutes — allowing healthcare providers to deliver timely, evidence-based care and minimise unnecessary delays in treatment.
A common infection with costly consequences
Urinary tract infections are among the most frequently diagnosed bacterial conditions, impacting more than 400 million people globally every year. Traditional diagnosis often takes days, during which broad-spectrum antibiotics are prescribed pre-emptively — a practice that can result in inadequate treatment and increased antimicrobial resistance (AMR). The PA-100 AST System improves this process with 84% sensitivity and 99% specificity, enabling precise antibiotic use and helping stem the tide of AMR.
Alain Baverel, President & CEO Sysmex Europe SE, remarked,
“The PA-100 AST System represents a pivotal innovation in the fight against antimicrobial resistance. By providing clinicians with rapid and precise diagnostic insights, we can transform how urinary tract infections are treated globally. This tool not only benefits patients but also strengthens the financial sustainability of healthcare systems.”
Projected healthcare savings in Spain
A new economic model, using Spain’s public health system as a reference, forecasts potential savings of approximately €323 million within the first year if the PA-100 AST System is widely implemented. The modelling attributes these savings to fewer complications, reduced hospital admissions, and lower productivity losses, with cumulative benefits increasing over a three-year period.
Takashi Ono, Member of the Managing Board and Senior Executive Officer & Managing Director of Sysmex Corporation, commented,
“By addressing one of the leading causes of antibiotic misuse, Sysmex’s PA-100 AST System aligns perfectly with global efforts to combat antimicrobial resistance. The system empowers healthcare providers with the data needed to make the right decision at the right time, benefiting patients and public health alike.”
Awarded for innovation and global impact
In recognition of its contribution to combating AMR, the PA-100 AST System received the Longitude Prize — a highly competitive £8 million award that honours solutions aimed at reducing antibiotic misuse. The accolade reinforces the importance of the system in advancing global health outcomes and ensuring sustainable infection control practices.
Smart design, faster results
The PA-100 AST System utilises a compact cartridge, comparable in size to a smartphone, to detect bacteriuria in just 15 minutes and determine appropriate antibiotics within the next 30. This rapid approach dramatically improves time-to-treatment and reduces the risk of complications associated with delayed care.